Alessi Isabella, Banton Kaysie L, J Sliter, C Zaw-Mon, Ch Palacio, Rj Ryznar, D Bar-Or
College of Osteopathic Medicine, Rocky Vista University, Centennial, CO, USA.
Trauma Research, Swedish Medical Center, Englewood, CO, USA.
Mol Pain. 2025 Jan-Dec;21:17448069251327840. doi: 10.1177/17448069251327840. Epub 2025 Mar 11.
The opioid crisis has highlighted the urgent need for alternative pain management strategies. This review explores novel non-opioid targets and pathways involved in pain modulation, highlighting advancements in understanding and therapeutic potential. Pain, a multifaceted phenomenon with nociceptive, neuropathic, and inflammatory components, involves intricate molecular signaling cascades. Key pathways reviewed include voltage-gated sodium channels (Nav1.7, Nav1.8, Nav1.9), inflammasome complexes (NLRP3), the kynurenine pathway, prostaglandins, and bradykinin-mediated signaling. Emerging therapeutics such as selective Nav channel blockers, NLRP3 inhibitors, kynurenine pathway modulators, EP receptor antagonists, and bradykinin receptor antagonists offer promising alternatives to opioids. Despite challenges in clinical translation, these developments signal a paradigm shift in pain management, with precision-focused therapies poised to address unmet needs. This review emphasizes the importance of integrating molecular insights into the development of safer, more effective analgesics, setting the stage for transformative advancements in non-opioid pain relief.
阿片类药物危机凸显了对替代疼痛管理策略的迫切需求。本综述探讨了参与疼痛调节的新型非阿片类靶点和途径,突出了在理解和治疗潜力方面的进展。疼痛是一种具有伤害性、神经性和炎症性成分的多方面现象,涉及复杂的分子信号级联反应。所综述的关键途径包括电压门控钠通道(Nav1.7、Nav1.8、Nav1.9)、炎性小体复合物(NLRP3)、犬尿氨酸途径、前列腺素和缓激肽介导的信号传导。新型疗法,如选择性钠通道阻滞剂、NLRP3抑制剂、犬尿氨酸途径调节剂、EP受体拮抗剂和缓激肽受体拮抗剂,为阿片类药物提供了有前景的替代方案。尽管在临床转化方面存在挑战,但这些进展标志着疼痛管理的范式转变,精准聚焦疗法有望满足未满足的需求。本综述强调了将分子见解整合到更安全、更有效的镇痛药开发中的重要性,为非阿片类疼痛缓解的变革性进展奠定了基础。